Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
Phase 1
- Conditions
- Influenza, Human
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Nova Immunotherapeutics Limited
- Target Recruit Count
- 102
- Registration Number
- NCT02500680
- Locations
- 🇺🇸
Saint Louis University School of Medicine, Saint Louis, Missouri, United States
News
No news found